Background/Aims: Treatment time is associated with survival in hemodialysis (HD) patients and with convection volume in hemodiafiltration (HDF) patients. High-volume HDF is associated with improved survival. Therefore, we investigated whether this survival benefit is explained by treatment time. Methods: Participants were subdivided into four groups: HD and tertiles of convection volume in HDF. Three Cox regression models were fitted to calculate hazard ratios (HRs) for mortality of HDF subgroups versus HD: (1) crude, (2) adjusted for confounders, (3) model 2 plus mean treatment time. As the only difference between the latter models is treatment time, any change in HRs is due to this variable. Results: 114/700 analyzed individuals were treated with high-volume HDF. HRs of high-volume HDF are 0.61, 0.62 and 0.64 in the three models, respectively (p values <0.05). Confidence intervals of models 2 and 3 overlap. Conclusion: The survival benefit of high-volume HDF over HD is independent of treatment time.

Keywords:
Convection volume, Hemodiafiltration, Hemodialysis, Mortality, Survival, Treatment time
1.
Yoshino M, Kuhlmann MK, Kotanko P, Greenwood RN, Pisoni RL, Port FK, Jager KJ, Homel P, Augustijn H, de Charro FT, Collart F, Erek E, Finne P, Garcia-Garcia G, Grönhagen-Riska C, Ioannidis GA, Ivis F, Leivestad T, Løkkegaard H, Lopot F, Jin DC, Kramar R, Nakao T, Nandakumar M, Ramirez S, van der Sande FM, Schön S, Simpson K, Walker RG, Zaluska W, Levin NW: International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006;17:3510-3519.
2.
Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999;10:1606-1615.
3.
Peralta CA, Shlipak MG, Fan D, Ordoñez J, Lash JP, Chertow GM, Go AS: Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol 2006;17:2892-2899.
4.
Gotch FA, Sargent JA: A mechanistic analysis of the national cooperative dialysis study (NCDS). Kidney Int 1985;28:526-534.
5.
Gotch F: The basic, quantifiable parameter of dialysis prescription is Kt/V urea; treatment time is determined by the ultrafiltration requirement; all three parameters are of equal importance. Blood Purif 2007;25:18-26.
6.
Shinzato T, Nakai S, Akiba T, Yamazaki C, Sasaki R, Kitaoka T, Kubo K, Shinoda T, Kurokawa K, Marumo F, Sato T, Maeda K: Survival in long-term haemodialysis patients: results from the annual survey of the Japanese society for dialysis therapy. Nephrol Dial Transplant 1997;12:884-888.
7.
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019.
8.
Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK: Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006;69:1222-1228.
9.
Twardowski ZJ: Treatment time and ultrafiltration rate are more important in dialysis prescription than small molecule clearance. Blood Purif 2007;25:90-98.
10.
Lacson E Jr, Brunelli SM: Hemodialysis treatment time: a fresh perspective. Clin J Am Soc Nephrol 2011;6:2522-2530.
11.
Held PJ, Levin NW, Bovbjerg RR, Pauly MV, Diamond LH: Mortality and duration of hemodialysis treatment. JAMA 1991;265:871-875.
12.
Lacson E Jr, Xu J, Suri RS, Nesrallah G, Lindsay R, Garg AX, Lester K, Ofsthun N, Lazarus M, Hakim RM: Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. J Am Soc Nephrol 2012;23:687-695.
13.
Hakim RM, Saha S: Dialysis frequency versus dialysis time, that is the question. Kidney Int 2014;85:1024-1029.
14.
Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009;20:645-654.
15.
Asci G, Tz H, Ozkahya M, Duman S, Demirci MS, Cirit M, Sipahi S, Dheir H, Bozkurt D, Kircelli F, Ok ES, Erten S, Ertilav M, Kose T, Basci A, Raimann JG, Levin NW, Ok E: The impact of membrane permeability and dialysate purity on cardiovascular outcomes. J Am Soc Nephrol 2013;24:1014-1023.
16.
Blankestijn PJ, Ledebo I, Canaud B: Hemodiafiltration: clinical evidence and remaining questions. Kidney Int 2010;77:581-587.
17.
Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, den Hoedt CH, van der Tweel I, Lévesque R, Nubé MJ, ter Wee PM, Blankestijn PJ: Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012;23:1087-1096.
18.
Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, Hur E, Demirci MS, Demirci C, Duman S, Basci A, Adam SM, Isik IO, Zengin M, Suleymanlar G, Yilmaz ME, Ozkahya M: Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF study. Nephrol Dial Transplant 2013;28:192-202.
19.
Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A: High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013;24:487-497.
20.
Mostovaya IM, Blankestijn PJ, Bots ML, Covic A, Davenport A, Grooteman MP, Hegbrant J, Locatelli F, Vanholder R, Nubé MJ: Clinical evidence on hemodiafiltration: a systematic review and a meta-analysis. Semin Dial 2014;27:119-127.
21.
Penne EL, van der Weerd NC, Bots ML, van den Dorpel MA, Grooteman MP, Lévesque R, Nubé MJ, ter Wee PM, Blankestijn PJ: Patient- and treatment-related determinants of convective volume in post-dilution haemodiafiltration in clinical practice. Nephrol Dial Transplant 2009;24:3493-3499.
22.
Chapdelaine I, Mostovaya IM, Blankestijn PJ, Bots ML, van den Dorpel MA, Lévesque R, Nubé MJ, ter Wee PM, Grooteman MP: Treatment policy rather than patient characteristics determines convection volume in online post-dilution hemodiafiltration. Blood Purif 2014;37:229-237.
23.
Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nubé MJ, ter Wee PM: Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch convective transport study. Semin Dial 2005;18:47-51.
24.
Clase CM, St Pierre MW, Churchill DN: Conversion between bromcresol green- and bromcresol purple-measured albumin in renal disease. Nephrol Dial Transplant 2001;16:1925-1929.
25.
Lowrie EG, Laird NM, Parker TF, Sargent JA: Effect of the hemodialysis prescription of patient morbidity: report from the national cooperative dialysis study. N Engl J Med 1981;305:1176-1181.
26.
Flythe JE, Curhan GC, Brunelli SM: Shorter length dialysis sessions are associated with increased mortality, independent of body weight. Kidney Int 2013;83:104-113.
27.
Miller JE, Kovesdy CP, Nissenson AR, Mehrotra R, Streja E, Van Wyck D, Greenland S, Kalantar-Zadeh K: Association of hemodialysis treatment time and dose with mortality and the role of race and sex. Am J Kidney Dis 2010;55:100-112.
28.
Gotch F, Kotanko P, Levin N: How can we improve the solute and fluid transport prescriptions in hemodialysis to improve patient outcomes? Blood Purif 2013;35:93-105.
29.
Daugirdas JT: Dialysis time, survival, and dose-targeting bias. Kidney Int 2013;83:9-13.
30.
Tattersall JE, Ward RA: Online haemodiafiltration: definition, dose quantification and safety revisited. Nephrol Dial Transplant 2013;28:542-550.
31.
Cornelis T, van der Sande FM, Eloot S, Cardinaels E, Bekers O, Damoiseaux J, Leunissen KM, Kooman JP: Acute hemodynamic response and uremic toxin removal in conventional and extended hemodialysis and hemodiafiltration: a randomized crossover study. Am J Kidney Dis 2014;64:247-256.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.